Get the latest Science News and Discoveries

Extended PSMA therapy safe and effective for prostate cancer patients - EurekAlert


Extended prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (177Lu-PSMA) beyond six cycles is an effective and well-tolerated treatment for metastatic castration-resistant prostate cancer patients, according to new research published in The Journal of Nuclear Medicine. Selected patients who received extended treatment—either continuously or following a treatment break—experienced a favorable median survival of 31.3 months from the first administration.

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of EurekAlert

EurekAlert

Related news:

News photo

Tiny crop-health sensors could help cut the cost of groceries - EurekAlert

News photo

New plant flowering gene atlas paves the way for advanced horticultural studies - EurekAlert

News photo

Severity of calls to US poison centers increases sharply for both adults, kids - EurekAlert